利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

34 条记录 (耗时 0.018 秒)

    TAA/CD40L vaccine for malaria
    23.
    发明授权
    TAA/CD40L vaccine for malaria 有权

    公开(公告)号：US09642901B1

    公开(公告)日：2017-05-09

    申请号：US14079830

    申请日：2013-11-14

    申请人： MicroVAX, LLC

    发明人： Albert B. Deisseroth

    IPC分类号： A61K39/015

    CPC分类号： A61K39/015 ,  A61K39/385 ,  A61K2039/5256 ,  C07K14/005 ,  C07K2319/06 ,  C07K2319/33 ,  C12N2710/10343 ,  C12N2710/20034 ,  C12N2760/16122 ,  C12N2760/16134 ,  Y02A50/412

    摘要： Provided are methods of selecting at least three domains of the malarial CSP protein for generating non-cross reacting neutralizing antibody immune responses to the malarial parasite which prevents an infection of a human being when bitten by a malaria infected mosquito. The method comprises priming an individual by administering a mixture of adenoviral expression vectors encoding fusion proteins or the fusion proteins themselves which comprises the malarial CSP antigen fragments linked to the extracellular domain of the CD40 ligand. The adenoviral expression vector comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing selected malarial sporozoite CSP antigen fragments linked to the CD40 ligand in order to block the attachment to or infection of the human liver cell(s) by the malarial sporozoite.

    TULAREMIA-TAA/CD40L VACCINE
    25.
    发明申请
    TULAREMIA-TAA/CD40L VACCINE 审中-公开
    TULAREMIA-TAA / CD40L疫苗

    公开(公告)号：US20140127252A1

    公开(公告)日：2014-05-08

    申请号：US14154710

    申请日：2014-01-14

    申请人： Albert B. Deisseroth

    发明人： Albert B. Deisseroth

    IPC分类号： A61K39/02

    CPC分类号： A61K39/0208 ,  A61K2039/53 ,  C07K14/005 ,  C07K2319/06 ,  C07K2319/33

    摘要： A Tularemia vaccine proposes to induce antibodies which through their binding to the target proteins of the vaccine strategy will inactivate the proteins essential to mediating the secretory function of the pilus proteins of the “type IV pilus proteins” or Tfp proteins, thereby impairing the formation of the pilus proteins on the surface of the FT which are needed for binding and entry of the FT into macrophages, and will inhibit the secretion of several factors of FT which are necessary for the virulence of the FT, and which are missing in attenuated strains of FT used in current attenuate strain vaccination strategies. The vaccine may be a mixture of DNA plasmids encoding TAA/ecdCD4OL protein vaccines in which the TAA is comprised of fragments of the following Tularemia proteins: Tfp, pilA, pilC, pilT, and pilQ,

    摘要翻译： 图雷雷米亚疫苗提出诱导抗体，通过它们与疫苗策略的靶蛋白的结合将使对介导“IV型绒毛蛋白”或Tfp蛋白的菌毛蛋白的分泌功能至关重要的蛋白质失活，从而损害了 在FT的表面上的FT的表面上的真菌蛋白质是FT结合并进入巨噬细胞所必需的，并且将抑制FT的毒性所必需的几种FT因子的分泌，并且其在减毒菌株中缺失 FT用于目前的减毒疫苗接种策略。 疫苗可以是编码TAA / ecdCD4OL蛋白疫苗的DNA质粒的混合物，其中TAA由以下Tularemia蛋白质的片段组成：Tfp，pilA，pilC，pilT和pilQ，

    CD40 LIGAND FUSION PROTEIN VACCINE
    26.
    发明申请
    CD40 LIGAND FUSION PROTEIN VACCINE 有权

    公开(公告)号：US20220143171A1

    公开(公告)日：2022-05-12

    申请号：US17391103

    申请日：2021-08-02

    申请人： MicroVAX, LLC

    发明人： Yucheng Tang ,  Albert B. Deisseroth

    IPC分类号： A61K39/145 ,  A61P31/04

    摘要： Provided are methods of generating an immune response to any of various antigens including foreign antigens such as infectious agent antigens. In general, the method comprises administering an expression vector encoding a transcription unit encoding a secretable fusion protein, the fusion protein containing the foreign antigen and CD40 ligand and also administering the encoded fusion protein. In another approach, an immune response to the foreign antigen is elicited using the encoded fusion protein without administering the vector. The invention methods may be used to immunize an individual against an infectious agent such as influenza virus. Methods of obtaining an immune response in older individuals also is described.

    Dengue hemorrhagic fever virus vaccine
    27.
    发明授权
    Dengue hemorrhagic fever virus vaccine 有权

    公开(公告)号：US10426827B1

    公开(公告)日：2019-10-01

    申请号：US14724409

    申请日：2015-05-28

    申请人： MicroVAX, LLC

    发明人： Albert B. Deisseroth

    IPC分类号： A61K39/12 ,  A61K39/00

    摘要： Provided are methods of selecting domains of the dengue hemorrhagic fever virus E protein for generating a neutralizing antibody immune response to the dengue hemorrhagic fever virus. The method comprises priming an individual by administering a mixture of expression vectors encoding fusion proteins or the fusion proteins themselves which comprises the DHFV E antigen fragment linked to the extracellular domain of the CD40 ligand. The expression vector comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing the DHFV E antigen fragment linked to the CD40 ligand. The methods may be used to immunize an individual against all four strains of dengue hemorrhagic fever virus.

    Vaccines for herpes simplex virus 1 and 2
    28.
    发明授权
    Vaccines for herpes simplex virus 1 and 2 有权

    公开(公告)号：US10166284B1

    公开(公告)日：2019-01-01

    申请号：US15689386

    申请日：2017-08-29

    申请人： MicroVAX, LLC

    发明人： Albert B. Deisseroth

    IPC分类号： C12N7/00 ,  A61K38/17 ,  A61K39/12 ,  A61K39/42 ,  C07K16/28 ,  C12N15/86 ,  C07K14/005 ,  A61K39/00 ,  A61K39/245

    摘要： The present invention is directed to novel compositions and methods against HSV (herpes simplex virus) 1 and 2. In brief, an epitope from a binding region of glycoprotein gD, important for binding or attachment of the HSV to the host cell, which is used to mediate the first essential function of infection, and three epitopes from binding regions of glycoprotein gB are used to mediate the second essential function of infection or the fusion of the HSV envelope with the cellular plasma membrane. Each of these epitopes is fused or linked with the extracellular domain of protein CD40L, to form a fusion protein, which fusion proteins are then combined in a mixture to form the inventive composition for acting against HSV 1 and 2.